Onconova Therapeutics Inc. [NASDAQ: ONTX] closed the trading session at $0.66 on 05/03/21. The day’s price range saw the stock hit a low of $0.6543, while the highest price level was $0.73. The company report on April 22, 2021 that Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC). The patient was dosed at the EB House Austria, a center of expertise for epidermolysis bullosa at the University Hospital Salzburg, Austria. Additional sites are anticipated to be opened in the UK and in the US to study this rare and genomically driven devastating disease.
In this open-label investigator-initiated study, 12 patients will receive either oral or intravenous rigosertib at the clinician’s discretion given the various clinical manifestations of the disease, which may dictate the need for either oral or intravenous administration of rigosertib. These patients have skin desquamation making intravenous access difficult, or may form esophageal strictures, which make oral administration difficult. Patients will receive either oral rigosertib in four-week cycles (three weeks on, one week off) for up to 13 cycles, with 560 mg of oral rigosertib in the morning and again in the afternoon, for a total of 1,120 mg/day. Alternatively, patients will receive intravenous (IV) rigosertib as a 72-hour IV infusion on days 1, 2 and 3 of eight 2-week cycles, and on days 1, 2 and 3 of nine 4-week cycles thereafter, with each 24-hour infusion consisting of 1,800 mg of rigosertib.
The stocks have a year to date performance of 42.34 percent and weekly performance of -13.90 percent. The stock has been moved at 150.19 percent over the last six months. The stock has performed -30.13 percent around the most recent 30 days and changed -2.36 percent over the most recent 3-months.
If compared to the average trading volume of 41.89M shares, ONTX reached to a volume of 8305003 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Onconova Therapeutics Inc. [ONTX]:
H.C. Wainwright have made an estimate for Onconova Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 01, 2018. The new note on the price target was released on January 17, 2018, representing the official price target for Onconova Therapeutics Inc. stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on ONTX stock.
The Average True Range (ATR) for Onconova Therapeutics Inc. is set at 0.08, with the Price to Sales ratio for ONTX stock in the period of the last 12 months amounting to 791.92. The Price to Book ratio for the last quarter was 22.10, with the Price to Cash per share for the same quarter was set at 0.08.
ONTX stock trade performance evaluation
Onconova Therapeutics Inc. [ONTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.90. With this latest performance, ONTX shares dropped by -30.13% in over the last four-week period, additionally plugging by 150.19% over the last 6 months – not to mention a rise of 115.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONTX stock in for the last two-week period is set at 38.78, with the RSI for the last a single of trading hit 36.70, and the three-weeks RSI is set at 41.02 for Onconova Therapeutics Inc. [ONTX]. The present Moving Average for the last 50 days of trading for this stock 0.9715, while it was recorded at 0.7289 for the last single week of trading, and 0.6663 for the last 200 days.
Onconova Therapeutics Inc. [ONTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Onconova Therapeutics Inc. [ONTX] shares currently have an operating margin of -10819.48. Onconova Therapeutics Inc.’s Net Margin is presently recorded at -10890.48.
Return on Total Capital for ONTX is now -281.63, given the latest momentum, and Return on Invested Capital for the company is -283.48. Return on Equity for this stock declined to -283.48, with Return on Assets sitting at -115.24.
Reflecting on the efficiency of the workforce at the company, Onconova Therapeutics Inc. [ONTX] managed to generate an average of -$2,096,417 per employee. Receivables Turnover for the company is 3.42 with a Total Asset Turnover recorded at a value of 0.01.Onconova Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Onconova Therapeutics Inc. [ONTX] stock
With the latest financial reports released by the company, Onconova Therapeutics Inc. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 40.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONTX.
Onconova Therapeutics Inc. [ONTX]: Insider Ownership positions
There are presently around $10 million, or 15.10% of ONTX stock, in the hands of institutional investors. The top three institutional holders of ONTX stocks are: VANGUARD GROUP INC with ownership of 8,260,810, which is approximately 19.154% of the company’s market cap and around 0.30% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 1,288,206 shares of the stock with an approximate value of $0.85 million in ONTX stocks shares; and PRINCIPAL FINANCIAL GROUP INC, currently with $0.77 million in ONTX stock with ownership of nearly New of the company’s market capitalization.
Positions in Onconova Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 22 institutional holders increased their position in Onconova Therapeutics Inc. [NASDAQ:ONTX] by around 3,779,557 shares. Additionally, 14 investors decreased positions by around 1,099,707 shares, while 9 investors held positions by with 9,750,429 shares. The mentioned changes placed institutional holdings at 14,629,693 shares, according to the latest SEC report filing. ONTX stock had 15 new institutional investments in for a total of 1,690,732 shares, while 6 institutional investors sold positions of 340,545 shares during the same period.